|
1 pahu (10 Vials)
| Ka nui: | |
|---|---|
▎ Hoʻolālā MOTS-c
Puna: PubChem |
Kaʻina: MRWQEMGYIFYPRKLR Ke Kumu Molekala: C101H152N28O22S2 Kaumaha Molekala: 2174.6g/mol Helu CAS: 1627580-64-6 PubChem CID: 146675088 Nā huaʻōlelo like: UNII-A5CV6JFB78 |
▎ MOTS-c Imi
He aha ke kumu noiʻi o MOTS-c?
ʻO ka mitochondrion kahi kahua koʻikoʻi no ka metabolism ikehu i loko o nā cell. No ka manawa lōʻihi, ua hana nā ʻepekema i ka noiʻi nui a hohonu e pili ana i ke ʻano a me ka hana o ka mitochondria. Ma kēia kaʻina hana, ua ʻike mālie ʻia ʻaʻole he kuleana koʻikoʻi wale nō ka mitochondria i ka hana ʻana i ka ikehu akā hiki ke komo pū i nā kaʻina physiological ʻē aʻe o nā cell ma o kekahi mau hana ʻike ʻole.
Me ka hoʻomau mau ʻana o nā ʻenehana noiʻi, ʻoi aku ka hoʻomohala ʻana o nā genomics a me nā ʻenehana proteomics, ua hiki ke ʻike i nā molekole pili i ka mitochondria hou. MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a mitochondria-derived peptide i hoʻopaʻa ʻia e ka 12S rRNA māhele o ka mitochondrial genome [1].
Ma o ka nānā ʻana i ka genome mitochondrial, ua ʻike nā kānaka ʻepekema i kekahi mau papa heluhelu liʻiliʻi (sORFs), hiki ke hoʻopili i kekahi mau peptides me nā hana kikoʻī. Ma hope o ka noiʻi hou a me ka hōʻoia, ua ʻike ʻia ʻo MOTS-c. Ua ʻike nā haʻawina ua hōʻike ʻia ʻo MOTS-c i nā ʻano kikoʻī i loko o ke kanaka a me nā holoholona. Hoʻohana nui ia i nā ʻiʻo skeletal ma o ke kahe koko, e hoʻonui ana i ka lawe ʻana a me ka hoʻohana ʻana i ka glucose, a laila e hoʻomaikaʻi ai i ka pale ʻana o ka insulin a me ka hoʻoponopono ʻana i ke kaulike metabolic [2].
Me ka hohonu o ka noiʻi ʻana, ua ʻike ʻia nā loli i ka ʻōlelo o MOTS-c pili loa i ka hanana a me ka ulu ʻana o nā maʻi ʻelemakule a me nā makahiki. No ka laʻana, emi ka pae o MOTS-c i ka plasma me ka makahiki (Zheng Y, 2013). I ka manawa like, ua hōʻike ʻia ʻo MOTS-c i mea e pono ai no nā maʻi e pili ana i ka makahiki, me ka maʻi diabetes, nā maʻi cardiovascular, osteoporosis, postmenopausal obesity, a me ka maʻi o Alzheimer [3].
He aha ka hana o ka MOTS-c?
Hoʻoponopono i ka hōʻike gene:
Hiki i ka MOTS-c ke hoʻokō i kāna mau hana physiological ma o ka hoʻoponopono ʻana i ka hōʻike gene. No ka laʻana, hiki iā ia ke hoʻoponopono i ka hōʻike ʻana o nā genes e like me GLUT4, STAT3, a me IL-10. Hoʻohana nui ʻo MOTS-c i kona hopena ma ka hoʻāla ʻana i ke ala hōʻailona AICAR-AMPK a hoʻopau i ka pōʻai folate-methionine i nā cell [4].
Ka hoʻomaikaʻi ʻana i ka insulin resistance:
Hiki i ka MOTS-c ke hōʻemi i ka pale ʻana i ka insulin a pale i ka maʻi maʻi type 2. Hiki ke pili ka hana o ka hana me ka pale ʻana i ka myostatin. Ua ʻike nā haʻawina e pili ana ka pae MOTS-c plasma me ka pae myostatin i loko o ke kino kanaka. Hiki i ka MOTS-c ke hoʻomaikaʻi i ka naʻau o ka insulin ma ke kāohi ʻana i ka hana o ka mea transcription upstream FOXO1 a hoʻemi i ka pae myostatin [5].
Hoʻoikaika i ka hoʻokaʻawale ʻana o nā ʻiʻo:
I loko o nā puʻupuʻu ʻiʻo, pili ʻo MOTS-c me STAT3 ma o kahi kumu hoʻopaʻa paʻa SH2 i ka ʻāina YIFY, e hōʻemi ana i ka hana transcriptional o STAT3, a laila e hoʻonui ai i ka hoʻokumu ʻana o ka myotube. Hiki i ka peptide MOTS-c ke hoʻonui i ka hoʻokumu ʻana o ka myotube o ke kanaka (LHCN-M2) a me ka ʻiole (C2C12) nā puʻupuʻu progenitor muscle a pale i nā cell muscle mai ka hōʻemi ʻana o ka nuclear myogenin staining i hoʻokomo ʻia e interleukin-6 (IL-6) [6].
Hoʻoponopono i ka hana mitochondrial:
Hiki i ka MOTS-c ke hoʻoponopono i ka metabolism mitochondrial. Ua hōʻike ʻia nā haʻawina e hiki ke hoʻonui i nā pae protein o nā māka biogenesis mitochondrial TFAM, COX4, a me NRF1 i ka mālama ʻana i nā cell mammalian me MOTS-c, akā hōʻike ʻia ka hoʻoheheʻe cytometry kahe i ka emi ʻana o ka mitochondria ma hope o ka mālama ʻana MOTS-c. Ua ʻike hou ʻia ka noiʻi ʻana e hiki i ka MOTS-c ke hoʻāla i ka mitochondrial fusion a hoʻonui i nā pae protein o ʻelua GTPases, OPA1 a me MFN2, he mea koʻikoʻi no ka hui ʻana o ka mitochondria mammalian. ʻO ka pale ʻana i kēia mau GTPases ʻelua a i ʻole ke kīkēkē ʻana i ka MFN2 ma o siRNA e hoʻopau i ka hiki o MOTS-c e hoʻolaha i ka translocation GLUT4 a me ka lawe ʻana i ka glucose [7].
ʻO MOTS-c kahi pahuhopu lapaʻau kūpono no nā maʻi e pili ana i ka ʻelemakule, me ka neurodegeneration, osteoporosis, maʻi cardiovascular, atherosclerosis, sarcopenia, type 2 diabetes mellitus, a me ka momona.
Puna:PubMed [8]
He aha nā noi o MOTS-c?
Hoʻomaikaʻi i nā maʻi pili makahiki
Ka pilina me ka ʻelemakule:
ʻO MOTS-c kahi peptide i loaʻa i ka mitochondria, a ua pili pono nā loli i kāna hōʻike i ka hanana a me ka ulu ʻana o nā maʻi ʻelemakule a me nā makahiki. I ka makahiki o ka poʻe, e emi ana ka pae o MOTS-c. Ua ʻike nā haʻawina he hopena koʻikoʻi ka hoʻoikaika kino i ka hōʻike ʻana o MOTS-c, a hiki i ka MOTS-c ke hoʻopili i ka hopena anti-aging o ka hoʻoikaika kino [3].
Diabetes:
Hiki i ka MOTS-c ke hoʻomaikaʻi i ka glucose o ke kino a me ka metabolism lipid, hoʻoikaika i ka hana mitochondrial i loko o nā pūnaewele, a hoʻemi i ka pane inflammatory maʻi. No nā poʻe maʻi maʻi maʻi, e emi ana ka pae o MOTS-c i ka plasma. Hiki i ka MOTS-c ke hoʻoponopono i ka homeostasis metabolic ma o ka hoʻonui ʻana i ka glucose a me ka hoʻomaikaʻi ʻana i ka ʻike insulin, a he hopena maikaʻi ia i ka pale ʻana i ka maʻi diabetes type 2 [8].
ʻO nā maʻi cardiovascular:
ʻO ka hoʻoponopono hou ʻana o ka naʻau a me ka hana ʻole ʻana he mau pilikia maʻamau o ka maʻi diabetes, e alakaʻi pinepine ana i nā hanana cardiovascular koʻikoʻi. Hiki i ka MOTS-c ke hoʻomaikaʻi i ka hana endothelial vascular a he pahuhopu therapeutic hou no ka hoʻopiʻi cardiovascular o ka maʻi diabetes. Ua hōʻike nā haʻawina e hiki i ka MOTS-c ke hoʻoponopono i ka pōʻino mitochondrial myocardial i nā ʻiole diabetic a pale i nā hana systolic a me ka diastolic cardiac [9].
Osteoporosis: Hiki i ka MOTS-c ke hoʻoikaika i ka hoʻonui ʻana, ka ʻokoʻa, a me ka mineralization o nā osteoblasts, ke kāohi i ka genesis osteoclast, a hoʻoponopono i ka metabolism iwi a me ka hoʻoponopono hou ʻana o ka iwi. Hiki i ka hoʻomaʻamaʻa ke hoʻoponopono maikaʻi i ka ʻōlelo o MOTS-c, akā ʻaʻole maopopo ke ʻano hana e hoʻoponopono ai i ka MOTS-c i nā iwi [10].
Nā maʻi ʻē aʻe
ʻO ka fibrosis pulmonary:
ʻO ka pulmonary fibrosis kahi maʻi maʻi maʻi maʻi me ka maikaʻi ʻole o ka wānana, a ʻaʻole maopopo ka etiology a me ka pathogenesis. ʻO ka mitochondrial open reading frame o 12S rRNA-c (MOTS-c) he peptide i hoʻopaʻa ʻia e ka mitochondrial genome, he hopena maikaʻi ia i ka glucose a me ka lipid metabolism, cellular a me mitochondrial homeostasis, a me ka hōʻemi ʻana o ka pane inflammatory systemic, a hiki paha ke hana mimetic. Ke manaʻo nei kēia loiloi e loiloi piha i nā palapala e pili ana i ke kuleana o MOTS-c i ka hoʻomaikaʻi ʻana i ka ulu ʻana o ka pulmonary fibrosis a ʻike i nā pahuhopu therapeutic kūikawā no nā hoʻolālā lapaʻau e hiki mai ana [11].
ʻO Duchenne muscular dystrophy:
ʻO MOTS-c kahi peptide bioactive i loaʻa mai i ka mitochondria me nā waiwai i hoʻopaʻa ʻia i ka ʻiʻo, hiki ke hoʻonui i ka glycolytic flux a me ka mana hana ikaika o nā ʻiʻo dystrophic in vitro a in vivo, e hoʻonui ai i ka uptake a me ka hana o ka phosphonodiamidite morpholino oligomers (PMO) i nā mdx mice. Hiki i ka hoʻokele manawa lōʻihi o MOTS-c a me PMO ke hoʻoulu i ka hōʻike ʻana o nā pae therapeutic o ka dystrophin i nā ʻiʻo peripheral, hoʻomaikaʻi i ka hana ʻiʻo a me ka pathology o nā ʻiole mdx, a ʻaʻohe mea ʻona [12].
ʻO ka momona a me ka ʻiʻo atrophy:
ʻO ka momona a me ka maʻi maʻi type 2 he mau maʻi metabolic e pili pinepine ana me ka sarcopenia a me ka hana ʻino. ʻO MOTS-c, ma ke ʻano he hormone systemic, komo i ka homeostasis metabolic. Ua ʻike nā haʻawina e pili ana ka pae MOTS-c plasma me ka pae myostatin i loko o ke kino kanaka. Hiki i ka MOTS-c ke pale i ka atrophy i hoʻokomo ʻia i ka palmitic acid o nā myotubes C2C12 like ʻole a hoʻemi i ka pae myostatin i loko o ka plasma o nā ʻiole momona i hoʻokomo ʻia i ka meaʻai. Ma ke kāohi ʻana i ka myostatin, hiki i ka MOTS-c ke mālama i ka atrophy muscle skeletal ma muli o ke kū ʻana o ka insulin a me nā ʻano ʻano atrophy ʻē aʻe me ka sarcopenia [5].
ʻO ka pilikia o nā maʻi metabolic i ka poʻe i pakele i ka maʻi kanesa:
ʻO nā wahine i loaʻa i ka mālama ʻana i ka maʻi maʻi umauma, ua piʻi nui ka pilikia o nā maʻi cardiovascular, diabetes, a me ka momona, a hiki i ka hoʻoikaika kino ke hoʻēmi i kēia mau hopena ʻaoʻao. Loaʻa i ka MOTS-c ka hana hoʻoikaika kino a loaʻa nā hopena maikaʻi i ka metabolism a me ka hiki ke hoʻoikaika kino. Ua ʻike nā haʻawina he 16-week aerobic a me ka hoʻoikaika ʻana i ka hoʻoikaika kino hiki ke hoʻonui i ka pae MOTS-c i ka poʻe ola maʻi maʻi umauma non-Hepanika, akā ʻaʻohe hopena koʻikoʻi i ka poʻe ola maʻi maʻi umauma Hepanika. ʻO ka piʻi ʻana o ka pae MOTS-c i hoʻoulu ʻia e ka hoʻomaʻamaʻa ʻana i nā mea ola maʻi umauma non-Hepanika e pili ana i ka hoʻomaikaʻi ʻana i ka naʻau o ka insulin, a laila e hōʻemi ana i ka hopena o nā comorbidities [13].
I ka hopena, ma ke ʻano he 16-amino acid polypeptide i hoʻopili ʻia e ka mitochondrial genome, MOTS-c ke kuleana nui i ka hoʻoponopono metabolic o ke kino, pale i ke kaumaha, a me ka pale ʻana a me ka mālama ʻana. Hiki iā ia ke hoʻomaikaʻi maikaʻi i ka homeostasis o ka glucose a me ka lipid metabolism, hoʻonui i ka naʻau o ka insulin, a ke kāohi i ka hōʻike ʻana o myostatin, e hōʻoluʻolu maikaʻi i ka maʻi diabetes type 2, ka momona, a me ka atrophy muscle pili. I ka manawa like, ma ka hoʻoponopono ʻana i ka biogenesis mitochondrial a me ka hui ʻana, hoʻonui ʻo MOTS-c i ka mana antioxidant o ka cell a keʻakeʻa i ka pane inflammatory, e hōʻike ana i ka hiki ke therapeutic no nā maʻi maʻi e like me nā maʻi cardiovascular, osteoporosis, a me ka pulmonary fibrosis. ʻO ka mea koʻikoʻi, ma ke ʻano he mea koʻikoʻi o ka kamaʻilio mitochondria-nucleus, hiki i ka MOTS-c ke hoʻohālikelike i nā hopena o ka hoʻoikaika kino a hoʻopaneʻe i ke kaʻina hana ʻelemakule. Hoʻopili maikaʻi ʻia kona pae me nā maʻi e pili ana i ka makahiki, a hiki i ka supplementation exogenous ke hoʻohuli i nā maʻi metabolic a keʻakeʻa i ka hoʻopiʻi viral. ʻIke ʻia ʻo ia ʻo ka 'hormone mitochondrial'.
No ka mea kakau
ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.
Mea kākau moʻolelo ʻepekema
He haumāna ʻo Dieli-Conwright CM me ka mana koʻikoʻi i ke kahua interdisciplinary o ka oncology a me ka ʻepekema hoʻoikaika kino. Ke lawelawe nei ʻo ia ma ke ʻano he kumu kaukaʻi o ka lāʻau lapaʻau ma ke Kula Lapaʻau ʻo Harvard a me ka Dana-Farber Cancer Institute a paʻa i kahi kūlana kumu kumu ma ka 'Oihana Nutrition ma ke Kula ʻo Harvard TH Chan School of Public Health. ʻO ka noiʻi a Kauka Dieli-Conwright ke nānā aku nei i ka ʻimi ʻana i ka hopena o ka hoʻoikaika kino i ka poʻe maʻi maʻi maʻi, ʻoi aku ka maikaʻi o ka hoʻoikaika kino e hoʻomaikaʻi i ka hana physiological, olakino iwi, a me ka maikaʻi o ke ola o nā maʻi maʻi kanesa. Hoʻopili ʻia kāna ʻoihana kula i nā ʻano he nui e like me ka biology, kinesiology, olakino lehulehu, a me biokinesiology. Ua hoʻopau ʻo ia i kāna mau haʻawina ma nā kula e like me California State University, Northridge, a me ke Kulanui o Southern Kaleponi a hoʻopau i kāna noiʻi postdoctoral ma City of Hope National Medical Center. Ua paʻi nui ʻia nā holomua noiʻi a Kauka Dieli-Conwright i loko o nā puke pai ʻepekema like ʻole, a ʻo kāna hana e pili ana i nā ʻano aʻoaʻo lehulehu e like me ke olakino lehulehu, ka meaʻai, ka ʻōnaehana cardiovascular, a me ka cardiology, e hāʻawi ana i nā hōʻike ʻepekema koʻikoʻi no ka hoʻoponopono hou ʻana a me ka hoʻokele olakino o nā maʻi maʻi maʻi. Ua helu ʻia ʻo Dieli-Conwright CM ma ka ʻōlelo kuhikuhi [13].
